BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Molecular Detection Inc. Completes $1.9 Million Series B Financing For Detect-Ready(R) Panels For Infectious Disease Diagnosis


4/16/2012 9:37:44 AM

WAYNE, Pa., April 16, 2012 /PRNewswire/ -- Molecular Detection Inc. (MDI), a company developing Detect-Ready® tests designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has completed a $1.9 million Series B recapitalization financing. All existing MDI investors, including MentorTech Ventures, Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group participated. The Series B recapitalization financing is in addition to a $1.5 million funding round announced by MDI earlier this year.

The funds will be used primarily to further advance MDI's Detect-Ready MRSA Panel and to develop MDI's new molecular diagnostic panels for the detection of sepsis and gastrointestinal (GI) infections in hospitalized patients.

"This is an exciting time as we advance the development and commercialization of our Detect-Ready tests for serious infections that are prevalent in hospitals," said Todd Wallach, CEO and chairman of MDI. "We appreciate the continuing support of our investors, which will enable us to expand our market presence worldwide and continue development of our new panels for sepsis and GI infections."

The Detect-Ready MRSA Panel is CE-marked for the detection of MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-sensitive S. aureus) pathogens. It is the only marketed PCR-based MRSA screening test with the proven ability to discriminate accurately between these pathogens and other related bacteria. The Detect-Ready MRSA Panel is currently available in the UK, Germany, Ireland, Switzerland, Spain, Austria, the Netherlands, Belgium, Luxembourg, Australia and Israel, and is in late-stage development in the US.

MDI's Detect-Ready sepsis panel leverages MDI's patent-protected technology to pinpoint the source of the underlying infection and allow treatment to begin as soon as possible. Similarly, MDI's Detect-Ready gastrointestinal panel aims to be the first that can rapidly distinguish the source of serious GI infections in hospitalized patients. MDI plans to launch the sepsis and GI panels in the European Union during 2012.

About Molecular Detection
Molecular Detection Inc. (MDI), a US-based company with offices in Wayne, PA, Tunbridge Wells, UK and Jerusalem, Israel, is developing and commercializing sample-to-answer Detect-Ready® molecular diagnostic tests for the detection of infectious diseases. The company's first product, a ready-to-use, rapid detection panel for hospital-based MRSA screening, is commercially available in the EU, Australia and the Middle East. The Detect-Ready MRSA Panel provides increased accuracy, faster time to results and more efficient utilization of hospital resources compared to other MRSA diagnostic products. MDI's real-time PCR tests are based on novel patented technologies for differential diagnosis and room-temperature stabilization. For more information, visit www.detect-ready.com.

Contacts:


Molecular Detection Inc.:

Media:

Todd Wallach

Barbara Lindheim

Chief Executive Officer

BioCom Partners

(215) 896-7001

(212) 854-2276 x201


blindheim@biocompartners.com

SOURCE Molecular Detection Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES